NCT00642278 – A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm Posted on October 20, 2014 by tsuperadmin -
NCT00543725 – A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects. Posted on October 20, 2014 by Jessica Ritchie -
NCT00540449 – A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects Posted on October 20, 2014 by Jessica Ritchie -
NCT00638690 – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy Posted on October 20, 2014 by tsuperadmin -
NCT00240721 – A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study Of The Safety And Efficacy Of Two Doses Of Topiramate For The Treatment Of Acute Manic Or Mixed Episodes In Subjects With Bipolar I Disorder With An Optional Open-Label Extension Posted on October 20, 2014 by tsuperadmin -
NCT00237289 – Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting Posted on October 20, 2014 by tsuperadmin -
NCT00266552 – The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Posted on October 20, 2014 by tsuperadmin -
NCT00250354 – The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Posted on October 20, 2014 by tsuperadmin -
NCT00236470 – Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders – an Open Label Follow-up Trial of CR002020 Posted on October 20, 2014 by tsuperadmin -
NCT00236444 – Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders Posted on October 20, 2014 by tsuperadmin -
The YODA Project